NovoCure Ltd
(BSP:N2VC34)
R$
7.08
(0%)
Market Cap: 820.01 Mil
Enterprise Value: -189.53 Mil
PE Ratio: 0
PB Ratio: 5.16
GF Score: 46/100 Novocure Ltd at Piper Sandler Healthcare Conference (Virtual) Transcript
Nov 30, 2021 / 06:00PM GMT
Jason M. Bednar
Piper Sandler & Co., Research Division - VP & Senior Research Analyst
All right. Hello, and thanks for joining Piper Sandler's 33rd Annual Healthcare Conference, again, in a virtual setting here this year. Hopefully, we can all be back again in-person next year. This is Jason Bednar of Piper Sandler's MedTech team. And I'm pleased to have with me today from NovoCure, Executive Chairman, Bill Doyle; and CFO, Ashley Cordova.
Bill and Ashley, thanks for joining us today.
Ashley Cordova
NovoCure Limited - CFO & VP of IR
Thank you.
William F. Doyle
NovoCure Limited - Executive Chairman
Our pleasure.
Jason M. Bednar
Piper Sandler & Co., Research Division - VP & Senior Research Analyst
I'll get started with questions here in a moment. But for those investors that are tuning in via the live webcast, please feel free to submit your own questions via the chat box at the bottom of your screen or you can e-mail them to me directly at
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot